Amgen Settles On Bevacizumab And Trastuzumab

Genentech Had Failed To Enjoin Sales Of Biosimilars In US

Door
Amgen is now seemingly in the clear for Mvasi and Kanjinti • Source: Shutterstock

More from Legal & IP

More from Generics Bulletin